$Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma$

Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma

Subcutaneous daratumumab (DARA SC; daratumumab co-formulated with recombinant human hyaluronidase PH20) is administered in ~ 5 min and demonstrates safety and efficacy comparable to intravenous daratumumab, with low infusion-related reaction (IRR) rates in global populations. This open-label, multic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2021, Vol.113 (1), p.112-121
Hauptverfasser:	Shibayama, Hirohiko, Matsumoto, Morio, Kosugi, Hiroshi, Shibayama, Kazuhiro, Yamazaki, Hiroshi, Iida, Shinsuke
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antineoplastic Agents - administration & dosage Asian Continental Ancestry Group Cell Adhesion Molecules Drug Compounding Drug Delivery Systems Hematology Humans Hyaluronoglucosaminidase Immunomodulation Immunotherapy Injections, Subcutaneous Intravenous administration Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Oncology Original Article Pharmacokinetics Pharmacology Proteasome inhibitors Recurrence Safety Targeted cancer therapy Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!